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Abstract
Newborn screening is the largest genetic testing effort in the United States and is considered one 
of the ten great public health achievements during the first 10 years of the 21st century. For over 
35 years, the Newborn Screening Quality Assurance Program (NSQAP) at the US Centers for 
Disease Control and Prevention has helped NBS laboratories ensure that their testing does not 
delay diagnosis, minimizes false-positive reports, and sustains high-quality testing performance. It 
is a multi-component program that provides comprehensive quality assurance services for dried 
blood spot testing. The NSQAP, the Biochemical Mass Spectrometry Laboratory (BMSL), the 
Molecular Quality Improvement Program (MQIP) and the Newborn Screening Translation 
Research Initiative (NSTRI), aid screening laboratories achieve technical proficiency and maintain 
confidence in their performance while processing large volumes of specimens daily. The accuracy 
of screening tests could be the difference between life and death for many babies; in other 
instances, identifying newborns with a disorder means that they can be treated and thus avoid life-
long disability or severe cognitive impairment. Thousands of newborns and their families have 
benefited from reliable and accurate testing that has been accomplished by a network of screening 
laboratories and the NSQAP, BMSL, MQIP and NSTRI.
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1. Introduction
Newborn screening (NBS) is the largest genetic testing effort in the United States and is 
considered one of the ten great public health achievements during the first 10 years of the 
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21st century [1]. Screening tests are designed to detect asymptomatic newborns at risk for a 
disease from those who are not at risk. Effective screening of newborns, combined with 
follow-up diagnostic confirmatory testing and treatment, helps prevent morbidity and 
mortality. In the United States, public health laboratories or their associated laboratories 
routinely screen dried blood spot (DBS) specimens for inborn errors of metabolism and 
other disorders that require medical intervention [2]. The Centers for Disease Control and 
Prevention’s Newborn Screening Quality Assurance Program (NSQAP) helps NBS 
laboratories ensure that testing accurately detects these disorders, does not delay diagnosis, 
minimizes false-positive reports, and sustains high-quality testing performance [3]. For over 
35 years, NSQAP has performed this essential public health service, ensuring the quality and 
accuracy of screening tests for more than 4 million babies born each year in the United 
States.
All NBS laboratories in the United States must meet strict quality assurance (QA) criteria in 
order to perform testing on human specimens through the Clinical Laboratory Improvement 
Amendments (CLIA; http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/
index.html). They must participate in proficiency testing (PT) programs designed to evaluate 
the quality of laboratory performance on a periodic basis using specimens in the dried blood 
matrix. Proficiency testing examines the analytical performance of individual laboratories 
for specific assays, and is used to monitor laboratories’ continuing performance at one point 
in time. All PT challenges are designed to mimic actual newborn specimens, and thus should 
be assayed following the individual laboratories’ standard operating procedures.
The NSQAP provides comprehensive QA services that include PT and quality control (QC) 
materials for DBS testing. Thus, NSQAP enables laboratories to meet the QA requirement 
for verifying test accuracy and provides technical guidance to participating laboratories to 
help assure that no screen-positive cases are misclassified during routine screening 
activities.
Participation in NSQAP allows laboratories to gain testing confidence through an external 
QA program for comparative analysis of peer performance within and among methods [2]. 
All PT and QC materials simulate, as closely as possible, specimens that are appropriate for 
a variety of assay systems. These DBS materials are certified for homogeneity, accuracy, 
stability, and suitability for assays from different commercial sources. Moreover, NSQAP 
provides training in the preparation of DBS materials and some test methods. The program 
staff compiles and distributes summary data reports each year for the comparative 
assessment of methods used by participants.
This review presents the NSQAP’s expansion timeline (Section 1.1) and current program 
statistics (Section 1.2). In Sections 2 and 3 we present a detailed description of NSQAP’s PT 
and QC programs, highlighting our practices in support of NBS laboratory quality. Section 4 
details our program’s expansion since 2009, where two new laboratories were created to 
enhance programmatic support to newborn screening laboratories. In Section 5 we present a 
preview of our program’s future activities in response to current NBS laboratory needs.
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1.1. Newborn Screening Quality Assurance Program Timeline
The NSQAP began providing services to newborn screening laboratories in 1978, when the 
first thyroxine and thyroid-stimulating hormone QC materials in DBS were distributed 
(Figure 1). The first PT surveys for phenylketonuria (PKU) and Congenital Hypothyroidism 
were conducted in 1980. That same year, the NSQAP Filter Paper Evaluation Project was 
established after the development of a DBS-based quantitative radio-isotopic test to measure 
and monitor the performance characteristics of filter paper used to collect newborn 
screening specimens under a standardized protocol. This work resulted in the development 
of the laboratory standard, Clinical and Laboratory Standards Institute NBS01-A6 Approved 
Standard, that addresses issues associated with specimen collection, the filter paper 
collection device, and the transfer of blood onto filter paper [4]. The first distribution of QC 
materials for phenylalanine occurred in 1983. In 1988, NSQAP began distributing HIV-1 
QC and PT materials for HIV antibodies in DBS as part of the seroprevalence survey among 
childbearing women [5]. Galactose QC materials were initially offered in 1988, followed by 
the first galactosemia PT survey in 1989.
The first congenital adrenal hyperplasia (CAH) PT survey using 17-α-hydroxyprogesterone 
was distributed to NSQAP participants in 1990, followed by distribution of CAH QC 
materials in 1991. Additionally in 1991, proficiency testing for sickle cell disease and other 
hemoglobinopathies were added to the program. In 1994, NSQAP established the QA 
program for DNA confirmatory methods using DBS specimens for hemoglobins A, S, C, E 
and D. After a pilot PT survey, methionine was added in 1995 to both the growing amino 
acids PT panel and to the amino acid DBS QC materials. Molecular methods for detecting 
the cystic fibrosis (CF) mutation, F508del (p.Phe508del) in DBS were established in the 
NSQAP laboratory in 1997, along with the first biotinidase deficiency PT survey.
The introduction of tandem mass spectrometry (MS/MS)-based methods for the detection of 
phenylalanine in DBS [6] revolutionized the practice of newborn screening for amino acid, 
fatty acid oxidation, and organic acid metabolic disorders. In 2001, NSQAP launched a pilot 
PT survey for laboratories testing DBS by MS/MS for the detection of amino acid, fatty acid 
oxidation, and organic acid disorders. The program began distributing the galactose-1-
phosphate uridyltransferase (GALT) PT survey, as well as panels of DBS specimens for 
immunoreactive trypsinogen (IRT) in 2002. In 2004, NSQAP added a PT program for DBS 
that mimicked CF newborn specimens with elevated IRT levels and the F508del 
(p.Phe508del) mutation. The program’s expansion continued in 2005, when a pilot PT 
survey for Toxoplasma gondii antibodies was launched for laboratories performing 
Toxoplasmosis screening [7]. In 2006, NSQAP launched the CAH PT pilot survey to 
support laboratories evaluating a second tier MS/MS-based CAH assay [8], which involved 
the detection of other steroid markers and the establishment of a clinical algorithm to 
identify CAH-affected newborns. In 2007, NSQAP expanded its CF PT surveys to include 
separate DBS panels to test for CF mutations using molecular methods. IRT became an 
independent PT program and was not included in the CF Mutation Detection surveys. The 
expanded CF Mutation Detection survey enhanced the NSQAP’s expertise in molecular 
biology-based technology while establishing a solid foundation to assist participating 
laboratories with their DNA-based screening assays.
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In 2008, a PT survey for succinylacetone (a specific marker for Tyrosinemia type 1) was 
launched. Also in 2008, QC materials for lysosomal storage disorders (LSD) screening using 
DBS were offered to NBS laboratories, in collaboration with the Newborn Screening 
Translation Research Initiative (NSTRI) at CDC [9]. In 2011, NSQAP, in collaboration with 
NSTRI, began a PT program for T-cell receptor excision circle (TREC) analysis in DBS to 
detect Severe Combined Immunodeficiency (SCID). NSTRI initially worked with the 
Wisconsin and Massachusetts newborn screening programs to develop methods and DBS 
reference materials for the detection of TREC. Materials were prepared from human blood, 
including cord blood from unaffected individuals and modified adult blood depleted of 
mononuclear cells or leukocytes. Through the Model Performance Evaluation Survey 
(MPES) operated by NSTRI, the DBS reference materials were offered to all US and 
international laboratories that conducted routine NBS for SCID. Over one dozen US and 
international NBS laboratories evaluated the reference materials in seven collaborative 
surveys. Using the cumulative experience of the laboratories that tested the DBS TREC 
reference materials through MPES, NSQAP initiated the TREC PT survey for US 
laboratories-only with seven participants.
To further enhance NSQAP’s molecular expertise and capacity, the Molecular Quality 
Improvement Program (MQIP) was created in 2011, allowing expanded molecular 
characterization including CFTR gene sequencing and large deletion analysis of the CF 
Mutation Detection PT materials (Section 4.1). Also in 2011, MQIP, in collaboration with 
the Association of Public Health Laboratories (APHL), launched a laboratory site visit 
program to assess the molecular components of the newborn screening laboratory. In 
addition, the Molecular Resources website, a joint effort of MQIP and APHL, was created in 
2012, to provide screening specific molecular resources to newborn screening laboratories.
The Biochemical Mass Spectrometry Laboratory (BMSL) was created in 2011 (Section 4.2). 
Its mission is to work with public health laboratories, academic institutions and clinical 
laboratories to develop new MS-based assays to detect and monitor metabolic disorders, and 
enhance newborn screening laboratory performance through innovative approaches for 
biochemical marker detection.
In 2013 a pilot PT survey for two LSDs, Krabbe and Pompe disease, was started by NSTRI 
and NSQAP for US domestic laboratories. NSTRI prepared DBS specimens from human 
blood, including cord blood from unaffected individuals and leuko-depleted adult blood 
restored with lymphoblast cells derived from patients with either Krabbe or Pompe. The 
LSD PT program currently has seven participants.
The BMSL and NSQAP collaborated with the Genetic Disease Laboratory Branch of the 
California Department of Public Health to develop DBS QC materials for monitoring the 
performance of GALT screening tests [10]. The collaboration led to the launch of a GALT 
QC program in 2014. In addition, in 2014 the TREC PT program was expanded to all 
newborn screening laboratories worldwide and enrollment grew to thirty-eight laboratories.
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1.2. NSQAP Biomarker Coverage, Participant Enrollments and Program Statistics
The NSQAP offers DBS QA materials for 26 of 31 primary (core) disorders (two disorders 
are screened by point-of-care technologies), and 24 of 26 secondary disorders in the US 
Department of Health and Human Services Recommended Uniform Screening Panel 
(RUSP) [11] (Tables 1, 2). Additionally, NSQAP offers DBS QA materials for X-linked 
adrenoleukodystrophy (X-ALD), HIV and Toxoplasma gondii antibodies, and six lysosomal 
storage disorders. Moreover, DBS QA materials are offered for selected second-tier tests. 
These include CAH by MS/MS, CF mutation testing by DNA-based technology including 
71 CFTR mutations covering all of the 23 CFTR mutations recommended for screening by 
the American College of Medical Genetics (ACMG), branched-chain amino acids for 
MSUD by MS/MS, and second-tier propionic acidemia / methylmalonic acidemia. NSQAP 
serves 612 laboratories in 71 countries (as of December 2014). Annually, NSQAP produces 
approximately one million DBS to meet the QA and PT needs of its participating newborn 
screening laboratories worldwide. Enrollment in the NSQAP program is open to laboratories 
actively screening newborn populations using the DBS matrix. A Request for Participation 
Form may be downloaded from NSQAP’s website (http://www.cdc.gov/labstandards/
nsqap.html).
2. NSQAP Proficiency Testing Program
The NSQAP provides NBS laboratories with quarterly panels of five blind-coded DBS 
specimens in all PT programs (Table 3). Data is returned to the program through either a 
web-based, secured reporting system, or by email. Reports of individual laboratory 
performance and summary data by analyte and method are available within one week of the 
closure of the internet data-reporting system. For PT challenges, laboratories report the 
cutoff value for each analyte tested. While there is variability in cutoff values among 
laboratories, participants are evaluated by their choice of whether a specimen’s results are 
in-range or out-of-range based on their laboratory cutoff. The reported analytical values are 
also an important component of the overall grading algorithm because specimen assessments 
are based on the expected analytical values [3].
NSQAP summarizes annual false-positive and false-negative rates for PT challenges for 
laboratories based on qualitative results (clinical assessments) for analytes or disorders. 
When false-negative misclassifications are detected, laboratories receive immediate 
notification from NSQAP supervisory staff so that the source of the error can be investigated 
and steps can be taken to eliminate the risk of the error occurring again. False-positive 
results are identified as a tool for use by the laboratory in examining their performance 
metrics.
3. NSQAP Quality Control Program
The NSQAP QC materials allow participants to monitor the long-term stability of their 
commercial assay kits or in-house methods. They are intended to supplement the 
participants’ method- or kit-control materials. The NSQAP provides NBS laboratories with 
QC DBS specimens two times per year (Table 4). Sets of DBS QC materials consist of three 
or four levels of single or multiple analytes. The materials are prepared from pooled, adult 
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donor blood that has been hematocrit-adjusted. Each pool is divided into equal portions so 
that the sets of QC materials are prepared from the same blood matrix. The whole blood is 
stored at −20°C for two weeks to lyse the red blood cells. Before dispensing, the blood is 
thoroughly mixed to assure a homogenous preparation. A customized robotic liquid 
handling system applies 100-μL of whole blood aliquots onto blood collection devices (filter 
paper). The DBS are dried at ambient temperature overnight and packed the next day by 
layering each filter paper card between sheets of glassine paper. The QC materials are 
placed in low-gas permeable bags with several desiccant packets and stored at −20°C until 
distribution to participating laboratories. The concentration of analyte(s) in each set of QC 
materials is certified by NSQAP and BMSL and certification pages accompany each 
shipment of DBS QC materials.
4. Program Expansions: 2009–2014
In 2011, the Biochemical Mass Spectrometry Laboratory (BMSL) and the Molecular 
Quality Improvement Program (MQIP) were established at CDC to support the increasing 
needs of participants in the fields of mass spectrometry and molecular biology. The BMSL 
and MQIP collaborate and support the mission of NSQAP to provide quality assurance to 
newborn screening laboratories.
4.1. Molecular Quality Improvement Program (MQIP)
NBS laboratory methods have traditionally involved biochemical assays that detect the 
presence or absence of analytes or enzyme activities that indicate a particular disorder or 
subset of disorders. With the introduction of CF mutation screening and more recently SCID 
screening, the first primary NBS molecular assay, molecular technology has become part of 
routine NBS. The MQIP collaborates with NSQAP to provide molecular expertise in support 
of DNA-based PT programs and QA, and works closely with NBS laboratories to assist with 
the incorporation of primary and second-tier molecular assays into their routine workflow by 
providing technical assistance and molecular specific resources. The MQIP laboratories use 
cutting-edge technology to comprehensively characterize disease causing mutations from 
DBS materials. In addition, MQIP offers a variety of resources for QA to support 
laboratories using molecular methods for NBS.
The Molecular Assessment Program is an invited personalized site visit to assess the 
molecular components of the newborn screening laboratory covering all phases of testing 
including pre-analytical, analytical and post-analytical. The assessment also offers 
customized approaches for implementing new molecular methods. The MAP team is 
comprised of scientists from the MQIP, US newborn screening public health programs and a 
representative from APHL. The NBS Molecular Resources Website is another resource the 
MQIP has developed in collaboration with APHL [12]. The website contains molecular 
information tailored to the newborn screening laboratory’s needs and includes the MAP site 
visit portal and checklists, detailed information on molecular assays currently being utilized 
in newborn screening laboratories in the U.S., a section listing automation resources for 
molecular screening, and archived materials from past molecular training workshops and 
webinars. The MQIP also hosts an annual Newborn Screening Molecular Training Course 
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and Laboratory Workshop which consists of both lecture and laboratory segments that 
directly relate to the detection of newborn disorders using molecular methods.
4.2. Biochemical Mass Spectrometry Laboratory (BMSL)
MS/MS has become the standard for the screening of fatty acid, amino acid and organic acid 
metabolism disorders in newborns worldwide. Largely, laboratories follow the analytical 
methods described by Chace [6], who introduced the use of MS/MS for the detection of 
phenylalanine (biomarker for phenylketonuria) in DBS. These methods are used to detect 
more than fifty diagnostic metabolites, covering over forty metabolic disorders in newborns. 
Many of these disorders are included in the US Recommended Uniform Screening Panel 
(RUSP). MS/MS also enables the introduction of second-tier tests to improve disease 
detection specificity.
The BMSL, together with the NSQAP and the APHL, provides MS/MS QA services to 
ensure the quality of MS/MS-based screening activities worldwide. BMSL provides QC and 
PT DBS materials for galactosemia, amino acids disorders, fatty acid oxidation disorders, 
organic acid disorders, galactose-1-phosphate uridyltransferase, biotinidase, and second-tier 
assays for CAH and MSUD. The BMSL consults with public health laboratories to ascertain 
which markers should be included in NSQAP QA panels. It also houses the filter paper 
evaluation program, which includes the routine evaluations offered to filter paper 
manufacturers.
The BMSL and the NSQAP expanded their coverage of MS/MS-detected analytes in the 
offered QC and PT panels to now cover all primary biomarkers for all MS/MS-detectable 
core and secondary target disorders listed in the US RUSP. Furthermore, MS/MS-based 
second-tier testing materials have been developed successfully to improve newborn 
screening assay specificity for selected biomarkers. These activities, in addition to ensuring 
the quality of filter paper blood collection devices, support newborn screening laboratory 
efforts to identify newborns with inborn errors of metabolism, and provide a high level of 
confidence in the laboratory analytical phase.
4.3. Training Courses
One of the most important activities conducted by the CDC is hands-on laboratory trainings, 
and they are an integral part of the program’s mission. To date, our programs have 
developed three courses that offer an in-depth, hands-on training for NBS laboratorians in 
order to meet this critical need.
The BMSL offers an in-depth laboratory workshop on newborn screening using MS/MS 
technology. The 5-day intensive workshop, titled "Newborn Screening by Tandem Mass 
spectrometry (MS/MS): A Hands-On Course in Understanding Laboratory Issues and 
Interpreting Test Results.", is co-sponsored by APHL, and is conducted at the BMSL’s 
laboratories. The course features four MS/MS hands-on exercises designed to enhance 
understanding of the didactic portions of the workshop. The exercises cover routine MS/MS 
newborn screening tests, methods and MS source optimization strategies, as well as second-
tier testing using MS/MS methods. To date, over 25 laboratorians have benefited from the 
MS/MS training course.
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The MQIP offers a comprehensive hands-on training workshop using molecular technology 
for newborn screening. This 5-day workshop, titled “The Newborn Screening Molecular 
Training Workshop” is cosponsored by APHL and incorporates lecture, group discussion 
and laboratory activities. The course offers lectures on newborn disorders that include a 
molecular component such as galactosemia, hemoglobinopathies, CF, MSUD, SCID and 
MCAD, as well as how to design a molecular laboratory such as setting up unidirectional 
workflow, comparing genotyping instrument platforms, and molecular data reporting and 
clinical interpretation. The laboratory activities include DNA extraction, gel electrophoresis, 
DNA quantitation, PCR-based mutation detection and genotyping, and liquid handling 
robotics. Since its inception, 52 participants have attended the Molecular Training 
Workshop.
The NSTRI conducts specialized SCID training for newborn screening programs teaching 
laboratorians how to produce and analyze DBS reference materials for the TREC assay used 
to detect SCID. These hands-on workshops are vital for the transfer of technology to states 
so that they can produce their own reference materials. As of December 2014, over 40 
laboratorians have participated in the SCID training workshop.
5. Future Directions
The NSQAP is in constant consultation with its participants and other stakeholders to stay 
abreast of near and future quality assurance needs. Every candidate analyte is evaluated for 
stability in the DBS matrix prior to its formal introduction into the NSQAP routine 
offerings. Depending on the analyte, NSQAP develops analytical methods, or uses 
commercially available kits to characterize new QA DBS materials. NSQAP sends pilot QA 
DBS materials to domestic and international partner laboratories that test them with their 
methods to assure that the materials are suitable for use by newborn screening methods 
worldwide.
In 2015, BMSL and NSQAP will launch a QA program for X-linked adrenoleukodystrophy 
(X-ALD), the most common human peroxisomal disorder. Individuals affected with X-ALD 
exhibit an accumulation of very long-chain fatty acids (VLCFA) due to their reduced 
oxidation within peroxisomes. The accumulation of C26:0 VLCFA has been shown to result 
in elevations of C26:0-lysophosphatidylcholine (C26:0-LPC) in X-ALD patients [13]. 
Currently, New York State is screening its population for X-ALD using the DBS matrix, and 
other jurisdictions are expected to initiate X-ALD newborn screening in the next two years.
The BMSL and NSQAP will also introduce a new PT program for glucose-6-phosphate 
dehydrogenase (G6PD) deficiency, the most common human enzyme defect [14]. It affects 
over 400 million people worldwide, most commonly males due to X-linked heredity. 
Individuals affected with G6PD deficiency have an increased risk of significant neonatal 
hyperbilirubinemia due to hemolytic crisis or baseline increase in red blood cell breakdown 
[15]. It is expected that the G6PD PT program will launch in 2015.
The BMSL is investigating the addition of the amino acids ornithine and glycine for 
introduction into the NSQAP amino acids QC program. Ornithine is used by one newborn 
screening program to screen for argininemia through the use of an arginine / ornithine ratio 
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[16]. Glycine levels can be measured by MS/MS in the DBS sample to screen for non-
ketotic hyperglycinemia (NKHG). While NKHG is not one of the disorders in the US 
RUSP, early diagnosis of NKHG might be particularly significant for atypical forms of the 
disease where early intervention may prove beneficial. Glycine is also measured by some 
newborn screening laboratories to assist in the diagnosis of NKHG, even though elevated 
glycine levels may not detectable by MS/MS newborn screening assays [17]. Both amino 
acids are currently under evaluation for stability and suitability for routine use in the 
NSQAP amino acids QC materials.
The MQIP is working towards developing a sustainable resource of QA materials to support 
NSQAP’s participants engaged in second-tier mutation detection for specific disorders such 
as CF and galactosemia. In order to offer molecular QA materials, donor samples that 
naturally contain the human genome with disease-specific mutations must be collected to 
test the accuracy of newborn disorder genotyping methods. Thus, QA materials cannot be 
created without collecting blood from affected donor participants; however, donors are often 
difficult to find due to the rarity of the mutations. In addition, blood collections only result 
in a finite number of DBS for QA. Using immortalized cell lines from these rare donors 
would allow for an infinite supply of a rare resource that can then be used to create DBS that 
will meet this need. The MQIP in support of the NSQAP is working towards creating DBS 
made from immortalized cell lines that will work robustly with different DNA extraction 
methods and a wide variety of genotyping methods and platforms. Once validated, it will be 
feasible for NSQAP to provide PT and PT and QC materials for screening methods that 
involve genotyping a panel of mutations.
6. Discussion
NSQAP is a proactive, multi-component QA program for a specialized area of public health 
testing [2]. NSQAP, BMSL, MQIP and NSTRI provide PT testing, QC materials, filter 
paper evaluations, special consultations, and technical assistance to public health and private 
laboratories engaged in NBS. The PT data-reporting is handled by an internet web site that 
permits participants to report their results online for each analyte, receive timely 
performance evaluation reports, and allows storage and retrieval access for historical data-
report summaries . The NSQAP serves as a focal point for NBS laboratories to address a 
variety of problems that may be encountered with the performance of laboratory-developed 
tests, and commercial kits / products with their manufacturers. Prompt consultation with the 
laboratories participating in the NSQAP may reduce the risk of catastrophic consequences of 
a delayed diagnosis to the newborn.
The NSQAP, BMSL, MQIP and NSTRI are designed to help screening laboratories achieve 
excellent technical proficiency and maintain confidence in their performance while 
processing large volumes of specimens daily. The programs continually strive to produce 
certified DBS materials for reference and QC analysis, to improve the quality and scope of 
services, and to provide immediate consultative and technical assistance. Over 14 million 
DBS QA materials have been distributed globally during 36 years of operation. Through our 
interactive efforts with the program’s participants, it works to meet their growing and 
changing NBS needs, always with an eye on future technological advances. The accuracy of 
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screening tests marks the difference between life and death for many babies; in other 
instances, identifying newborns with a disorder means that they can be treated and thus 
avoid life-long disability or severe cognitive impairment. In the United States, over 12,000 
babies each year are saved from deleterious health outcomes through newborn screening and 
early identification. Thousands of newborns and their immediate families have benefited 
from reliable and accurate testing that has been accomplished by a network of screening 
laboratories and the NSQAP, BMSL, MQIP and NSTRI.
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Figure 1. 
Newborn Screening Quality Assurance Program Timeline.
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Table 1
US Recommended Uniform Screening Panel Core Conditions.
Core Condition ACMG Code NSQAP QA Materials (Y/N)
Propionic acidemia PROP Y
Methylmalonic acidemia (methylmalonyl-CoA mutase) MUT Y
Methylmalonic acidemia (cobalamin disorders) Cbl A,B Y
Isovaleric acidemia IVA Y
3-Methylcrotonyl-CoA carboxylase deficiency 3-MCC Y
3-Hydroxy-3-methyglutaric aciduria HMG Y
Holocarboxylase synthase deficiency MCD Y
β-Ketothiolase deficiency βKT Y
Glutaric acidemia type I GA1 Y
Carnitine uptake defect/carnitine transport defect CUD Y
Medium-chain acyl-CoA dehydrogenase deficiency MCAD Y
Very long-chain acyl-CoA dehydrogenase deficiency VLCAD Y
Long-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency LCHAD Y
Trifunctional protein deficiency TFP Y
Argininosuccinic aciduria ASA Y
Citrullinemia type I CIT Y
Maple syrup urine disease MSUD Y
Homocystinuria HCY Y
Classic phenylketonuria PKU Y
Tyrosinemia type I TYR I Y
Primary congenital hypothyroidism CH Y
Congenital adrenal hyperplasia CAH Y
Biotinidase deficiency BIOT Y
Cystic fibrosis CF Y
Classic galactosemia GALT Y
Severe combined immunodeficiencies SCID Y
S,S Disease (Sickle cell anemia) Hb SS N
S, beta-Thalassemia Hb S/β Th N
S,C Disease Hb S/C N
Critical congenital heart disease CCHD N/A
Hearing loss HEAR N/A
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Table 2
US Recommended Uniform Screening Panel Secondary Conditions.
Secondary Condition ACMG Code NSQAP QA Materials (Y/N)
Methylmalonic acidemia with homocystinuria Cbl C,D Y
Malonic acidemia MAL Y
Isobutyrylglycinuria IBG Y
2-Methylbutyrylglycinuria 2MBG Y
3-Methylglutaconic aciduria 3MGA Y
2-Methyl-3-hydroxybutyric aciduria 2M3HBA Y
Short-chain acyl-CoA dehydrogenase deficiency SCAD Y
Medium/short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency M/SCHAD Y
Glutaric acidemia type II GA2 Y
Medium-chain ketoacyl-CoA thiolase deficiency MCAT Y
2,4 Dienoyl-CoA reductase deficiency DE RED Y
Carnitine palmitoyltransferase type I deficiency CPT IA Y
Carnitine palmitoyltransferase type II deficiency CPT II Y
Carnitine acylcarnitine translocase deficiency CACT Y
Argininemia ARG Y
Citrullinemia type II CIT II Y
Hypermethioninemia MET Y
Benign hyperphenylalaninemia H-PHE Y
Biopterin defect in cofactor biosynthesis BIOPT (BS) Y
Biopterin defect in cofactor regeneration BIOPT (REG) Y
Tyrosinemia type II TYR II Y
Tyrosinemia type III TYR III Y
Various other hemoglobinopathies Var Hb Y
Galactoepimerase deficiency GALE N
Galactokinase deficiency GALK N
T-cell related lymphocyte deficiencies - Y
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Table 3
NSQAP Proficiency Testing (PT) Programs as of December 2014.
PT Program (Number of Participants) Analytes Included in Each Program
Amino Acids (444) Arginine, Leucine, Phenylalanine, Tyrosine, Valine, Citrulline, Succinylacetone, Methionine
Acylcarnitines (315) C0(L), C3, C3DC, C4, C4OH, C5, C5:1, C5DC, C5OH, C6, C8, C10, C10:1, C10:2, C14, 
C14:1, C16, C16OH, C18, C18:1, C18OH
Hormones (376) Thyroid-Stimulating Hormone, Thyroxine, Total Galactose, 17- α-Hydroxyprogesterone
Immunoreactive Trypsinogen (211) Immunoreactive Trypsinogen
CF DNA (64) 71 Mutations
Hemoglobins* (73) Varied
UDOT* (65) Varied
Galactose-1-phosphate Uridyltransferase (125) GALT
Biotinidase Deficiency (199) Biotinidase
Second Tier CAH (17) 17-Hydroxyprogesterone, 4-Androstenedione, Cortisol, 11-Deoxycortisol, 21-Deoxycortisol
Lysosomal Storage Disorders* (7) Pompe, Krabbe
SCID (40) T-cell Excision Circles (TREC)
Toxoplasmosis gondii (10) Anti-Toxoplasma gondii Immunoglobulins M and G
HIV (28) Anti-HIV-1 Antibodies
*
Limited enrollment
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Table 4
NSQAP Quality Control (QC) Programs as of December 2014.
QC Program (Number of Participants) Analytes Included in Each Program
Amino Acids (398) Arginine, Leucine, Phenylalanine, Tyrosine, Valine, Citrulline, Succinylacetone, Methionine, 
Total Galactose
Acylcarnitines (284) C0(L), C2, C3, C3DC, C4, C4OH, C5, C5DC, C5OH, C6, C8, C10, C12, C14, C16, C16OH, 
C18, C18OH
Thyroid-Stimulating Hormone (323) Thyroid-Stimulating Hormone
Thyroxine (77) Thyroxine
17-Hydroxyprogesterone (211) 17-Hydroxyprogesterone
Immunoreactive Trypsinogen (185) Immunoreactive Trypsinogen
Galactose-1-phosphate Uridyltransferase (88) GALT
Lysosomal Storage Disorders Pompe, Krabbe, Niemann Pick A/B, Fabry, Gaucher,
(42) Mucopolysaccharidosis I
HIV-1 (28) Anti-HIV-1 Antibodies
X-ALD (4) 24:0 Lysophosphatidylcholine, 26:0 Lysophosphatidylcholine
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